Home 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

Tech Leaders: NEXCF, RBLX AUVI, AIMLF; Visionary CEOs Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Metaverse, HealthTech Wearables, and Clean Air Technologies
Business Software and Services Market Size [2022-2028] To Reach $813.4 Billion at a CAGR of 11